Alex Slanix Paul's Form 4 filing
ProMIS Neurosciences Inc. (PMN) · filed Feb 5, 2026
- Accession no.
- 0001493152-26-005410
- Filed
- Feb 5, 2026, 7:00 PM ET
- Trade date
- Feb 3, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $8.50M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Alex Slanix PaulCIK 0002092283 | Director |
| Yu FanCIK 0001668029 | 10% Owner |
| Ally Bridge Group (NY) LLCCIK 0001822947 | 10% Owner |
| Ally Bridge MedAlpha Master Fund L.P.CIK 0001831963 | 10% Owner |
| ABG Management Ltd.CIK 0001832106 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Common Shares | PPurchaseAcquired | +700,741 | $12.13F1 | +$8,499,988.33 | 943,090 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Common Shares | PPurchaseAcquired | +700,741 | –F1 | – | 700,741 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Remarks
Each of ABG Global Life Science Capital Partners V GP Limited, ABG Global Life Science Capital Partners V GP, L.P., Ally Bridge Group Global Life Science Capital Partners V, L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited will file a Form 3 in connection with the transactions reported herein and thereafter are expected to file Forms 4 jointly with the reporting persons.